PMID- 24318084
OWN - NLM
STAT- MEDLINE
DCOM- 20141203
LR  - 20220409
IS  - 1573-2649 (Electronic)
IS  - 0962-9343 (Linking)
VI  - 23
IP  - 5
DP  - 2014 Jun
TI  - Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what 
      is the responsiveness and minimal clinically important difference?
PG  - 1427-34
LID - 10.1007/s11136-013-0593-4 [doi]
AB  - PURPOSE: To evaluate the responsiveness of EQ-5D 3L in patients undergoing 
      intracranial glioma surgery and estimate the minimal clinically important 
      difference (MCID). MATERIALS AND METHODS: EQ-5D 3L index values from 164 patients 
      who underwent glioma surgery in the period 2007-2012 were analysed. 
      Responsiveness and MCID were estimated using a combination of distribution-based 
      and anchor-based methods. Karnofsky performance status served as an anchor. 
      RESULTS: Patients who improved functionally did not report significantly higher 
      EQ-5D 3L scores post operatively with a standardized response mean (SRM) of 0.04 
      (p = 0.13). Patients who deteriorated functionally reported significantly lower 
      EQ-5D 3L scores post operatively with a SRM of 0.72 (p < 0.001). With different 
      approaches, we determined a range of MCID values from 0.13 to 0.15. CONCLUSIONS: 
      EQ-5D 3L is responsive to changes when glioma patients are deteriorating 
      functionally after surgery but not responsive when the patients are improving. 
      The MCID values for EQ-5D 3L in glioma surgery seem higher than reported MCID 
      values for other types of cancers.
FAU - Sagberg, Lisa Millgard
AU  - Sagberg LM
AD  - Department of Neuroscience, Norwegian University of Science and Technology, 7491, 
      Trondheim, Norway, lisa.millgard.sagberg@ntnu.no.
FAU - Jakola, Asgeir S
AU  - Jakola AS
FAU - Solheim, Ole
AU  - Solheim O
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20131207
PL  - Netherlands
TA  - Qual Life Res
JT  - Quality of life research : an international journal of quality of life aspects of 
      treatment, care and rehabilitation
JID - 9210257
SB  - IM
MH  - Brain Neoplasms/drug therapy/*psychology/surgery
MH  - Chemotherapy, Adjuvant
MH  - Cross-Sectional Studies
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Glioma/drug therapy/*psychology/surgery
MH  - Health Status Indicators
MH  - Humans
MH  - Karnofsky Performance Status/statistics & numerical data
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading/psychology
MH  - Norway
MH  - Postoperative Period
MH  - Prospective Studies
MH  - Quality of Life/*psychology
MH  - Sickness Impact Profile
MH  - Surveys and Questionnaires/*standards
MH  - Time Factors
MH  - Treatment Outcome
MH  - Visual Analog Scale
EDAT- 2013/12/10 06:00
MHDA- 2014/12/15 06:00
CRDT- 2013/12/10 06:00
PHST- 2013/11/27 00:00 [accepted]
PHST- 2013/12/10 06:00 [entrez]
PHST- 2013/12/10 06:00 [pubmed]
PHST- 2014/12/15 06:00 [medline]
AID - 10.1007/s11136-013-0593-4 [doi]
PST - ppublish
SO  - Qual Life Res. 2014 Jun;23(5):1427-34. doi: 10.1007/s11136-013-0593-4. Epub 2013 
      Dec 7.